Antihypertensive Medications and Change in Stages of Chronic Kidney Disease

Overview

Journal Int J Chronic Dis

Date 2018 Apr 24

PMID 29682516

Citations 4

Authors

Marina Komaroff

Fasika Tedla

Elizabeth Helzner

Michael A Joseph

Affiliations

Soon will be listed here.

Abstract

Objectives: The goal of this study is to estimate the change in the relationships between use of five classes of antihypertensive medications and stages of Chronic Kidney Disease (CKD) in American adults treated for hypertension.

Methods: The US National Health and Nutrition Examination Survey (NHANES) data sets 1999-2012 were used with the final analytical sample of 3,045 participants. Population prevalence estimates were calculated using the NHANES survey design weights. Inferential analyses were done with binomial logistic regression models.

Results: The odds of advanced (3, 4, and 5 combined) versus early CKD stages (1 and 2 combined) were significantly higher among patients treated with Angiotensin Receptor Blockers (ARB) versus those not treated with ARB in 2009-2012 (adjusted odds ratio (95% confidence interval) = 2.52 (1.32-4.80)). From 1999 to 2012, the increase in this relationship was significant ( = 0.0023) for users of ARB polytherapy and in users of ARB in patients with albuminuria ( = 0.0031).

Conclusion: Aggressive pharmacological management of hypertension with ARB as add-on therapy may have accelerated kidney damage in American adults. However, prospective longitudinal studies are needed to establish proper temporal sequence in this relationship.

Citing Articles

A Resampling Method to Improve the Prognostic Model of End-Stage Kidney Disease: A Better Strategy for Imbalanced Data.

Shi X, Qu T, Van Pottelbergh G, van den Akker M, De Moor B Front Med (Lausanne). 2022; 9:730748.

PMID: 35321465 PMC: 8935060. DOI: 10.3389/fmed.2022.730748.

Oxidized Albumin as a Mediator of Kidney Disease.

Figueroa S, Araos P, Reyes J, Gravez B, Barrera-Chimal J, Amador C Antioxidants (Basel). 2021; 10(3).

PMID: 33800425 PMC: 8000637. DOI: 10.3390/antiox10030404.

Replicating medication trend studies using ad hoc information extraction in a clinical data warehouse.

Dietrich G, Krebs J, Liman L, Fette G, Ertl M, Kaspar M BMC Med Inform Decis Mak. 2019; 19(1):15.

PMID: 30658633 PMC: 6339317. DOI: 10.1186/s12911-018-0729-0.

Renal Dysfunction among Ghanaians Living with Clinically Diagnosed Hypertension in the Asutifi-South District: A Cross-Sectional Descriptive Study at the St. Elizabeth Hospital, Hwidiem.

Lokpo S, Osei-Yeboah J, Owiredu W, Ussher F, Orish V, Gadzeto F Int J Hypertens. 2018; 2018:8428063.

PMID: 30519488 PMC: 6241342. DOI: 10.1155/2018/8428063.

References

Ong K, Tso A, Lam K, Cheung B . Gender difference in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension. 2008; 51(4):1142-8. DOI: 10.1161/HYPERTENSIONAHA.107.105205. View

Tomlinson L, Abel G, Chaudhry A, Tomson C, Wilkinson I, Roland M . ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study. PLoS One. 2013; 8(11):e78465. PMC: 3819379. DOI: 10.1371/journal.pone.0078465. View

Wheeler D, Becker G . Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int. 2013; 83(3):377-83. DOI: 10.1038/ki.2012.425. View

Gu Q, Burt V, Dillon C, Yoon S . Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012; 126(17):2105-14. DOI: 10.1161/CIRCULATIONAHA.112.096156. View

. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1):S1-290. View

Parker 3rd T, Blantz R, Hostetter T, Himmelfarb J, Kliger A, Lazarus M . The chronic kidney disease initiative. J Am Soc Nephrol. 2004; 15(3):708-16. DOI: 10.1097/01.asn.0000112129.20838.3f. View

Egan B, Zhao Y, Axon R . US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010; 303(20):2043-50. DOI: 10.1001/jama.2010.650. View

. U.S. Department of Health and Human Services: Office of Disease Prevention and Health Promotion--Healthy People 2010. Nasnewsletter. 2002; 15(3):3. View

Hostetter T, Lising M . National Kidney Disease Education Program. J Natl Med Assoc. 2002; 94(8 Suppl):72S-75S. PMC: 2594171. View

10.

. Erratum: Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder.... Kidney Int Suppl (2011). 2019; 7(3):e1. PMC: 6341011. DOI: 10.1016/j.kisu.2017.10.001. View

11.

Wright Jr J, Williamson J, Whelton P, Snyder J, Sink K, Rocco M . A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22):2103-16. PMC: 4689591. DOI: 10.1056/NEJMoa1511939. View

12.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289(19):2560-72. DOI: 10.1001/jama.289.19.2560. View

13.

Yoon S, Burt V, Louis T, Carroll M . Hypertension among adults in the United States, 2009-2010. NCHS Data Brief. 2012; (107):1-8. View

14.

Nwankwo T, Yoon S, Burt V, Gu Q . Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013; (133):1-8. View

15.

Crim M, Yoon S, Ortiz E, Wall H, Schober S, Gillespie C . National surveillance definitions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012; 5(3):343-51. PMC: 3407684. DOI: 10.1161/CIRCOUTCOMES.111.963439. View

16.

. Standards of medical care in diabetes--2010. Diabetes Care. 2010; 33 Suppl 1:S11-61. PMC: 2797382. DOI: 10.2337/dc10-S011. View

17.

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View